New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.
A new imaging technology to grade tumour biopsies has been developed by a team of scientists led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London.
Publishing their results today in the journal Convergent Science Physical Oncology, they describe how their new method promises to significantly reduce the subjectivity and variability in grading the severity of cancers.
[Digistain] is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis.Professor Chris Phillips
Nearly all cancers are still diagnosed by doctors taking a sample of the tumour, a so-called biopsy, then slicing it thinly and staining it with two vegetable dyes used for more than 100 years. They look at this ‘H+E stained’ sample under a microscope and then judge the severity of the disease by eye alone.
Life-changing treatment decisions have to be based on this ‘grading’ process, yet it is well known that different practitioners given the same slice will only agree on its grade about 70% of the time, resulting in an overtreatment problem.
The team’s new ‘Digistain’ technology addresses this problem by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer. In particular, they measure the ‘nuclear-to-cytoplasmic-ratio’ (NCR): a recognized biological marker for a wide range of cancers.
Lead author Professor Chris Phillips, from the Department of Physics at Imperial, said: “Our machine gives a quantitative ‘Digistain index’ (DI) score, corresponding to the NCR, and this study shows that it is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis. “
In the experiment reported today, the team carried out a double-blind clinical pilot trial using two adjacent slices taken from 75 breast cancer biopsies. The first slice was graded by clinicians as usual, using the standard H+E protocol. It was also used to identify the so-called ‘region of interest’ (RoI), i.e. the part of the slice containing the tumour.
The team then used the Digistain imager to get a DI value averaged over the corresponding RoI on the other, unstained slice, and ran a statistical analysis on the results.
Professor Phillips said: “Even with this modest number of samples, the correlation we saw between the DI score and the H+E grade would only happen by chance 1 time in 1400 trials. The strength of this correlation makes us extremely optimistic that Digistain will be able to eliminate subjectivity and variability in biopsy grading.”
Proving its worth
The NCR factor that Digistain measures is known to be common to a wide range of cancers, as it occurs when the reproductive cell cycle gets disrupted in the tumour and cell nuclei get distorted with rogue DNA. It is likely that in the long run, Digistain could help with the diagnosis of all different types of cancer.
At a practical level, the researchers say that the Digistain imaging technology can easily and cheaply be incorporated into existing hospital labs, and be used by their staff. Professor Philips added: “It’s easy to prove its worth by checking it with the thousands of existing biopsy specimens that are already held in hospital archives. Together these facts will smooth the path into the clinic, and it could be saving lives in only a couple of years.”
The Latest on: Cancer diagnosis
via Google News
The Latest on: Cancer diagnosis
- MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis on February 18, 2019 at 7:57 pm
San Francisco, CA USA (UroToday.com) --MDxHealth SA announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for P... […]
- When Cancer Treatment Takes Away Your Sexual Desire on February 18, 2019 at 5:47 pm
It is understandable to experience a lack of libido when you are first diagnosed with cancer. Your focus quickly moves from your everyday, normal routine to, “Oh, my God, I have cancer!” This new real... […]
- The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025 on February 18, 2019 at 4:03 pm
Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cance... […]
- Very early marker of cardiac damage triggered by cancer treatment on February 18, 2019 at 3:05 pm
Researchers have identified a very early marker of cardiac damage in patients undergoing therapy with anthracyclines, a family of drugs commonly used to treat cancer. This finding will enable the earl... […]
- 30 Cancer Symptoms You Should Never Ignore on February 18, 2019 at 2:34 pm
You won’t always get a lump or a bump with cancer. The signs can be much less obvious—and they could point to other health issues as well. It’s key to discuss any of the following symptoms with your d... […]
- Acadiana teen diagnosed with rare cancer on February 18, 2019 at 10:57 am
PARKS, La. (KLFY) - An Acadiana teen is battling a rare form of cancer. It wasn't until about two weeks after a car accident last year, when his knee began to hurt, leading to the cancer diagnosis. Th... […]
- Mom gets new tongue made from arm after cancer diagnosis on February 18, 2019 at 7:42 am
A 58-year-old woman who was reportedly faced with either surgically removing part of her tongue or succumbing to cancer within months has had a new one fashioned out of a vein and pieces of her arm. J... […]
- Raising awareness of lung cancer risk in people with COPD on February 18, 2019 at 5:53 am
Early diagnosis of lung cancer is vital to improving survival. Figures from Cancer Research UK reveal that when diagnosed at its earliest stage, almost 6 in 10 people with lung cancer will survive ... […]
- Idaho WR diagnosed with kidney cancer on February 17, 2019 at 1:27 pm
Idaho wide receiver Collin Sather is battling advanced renal cancer, the program has announced. Renal cancer attacks the kidneys and most commonly attacks older men. According to the Idaho ... […]
via Bing News